Patents by Inventor Catherine Leblanc

Catherine Leblanc has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Organic Compounds
    Publication number: 20100298337
    Abstract: Compounds of formula (I) in free or salt or solvate form, where T1, T2, and T3 have the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle diseases and systemic skeletal disorders. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: January 9, 2009
    Publication date: November 25, 2010
    Inventors: Peter Hunt, Catherine Leblanc, Robert Alexander Pulz, Nikolaus Johannes Stiefl
  • Organic compounds
    Publication number: 20100210610
    Abstract: There are provided according to the invention compounds of formula (I), in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.
    Type: Application
    Filed: February 3, 2010
    Publication date: August 19, 2010
    Inventors: Kamlesh Jagdis Bala, Catherine Leblanc, David Andrew Sandham, Katharine Louise Turner, Simon James Watson, Lyndon Nigel Brown, Brian Cox
  • Organic Compounds
    Publication number: 20100210641
    Abstract: Compounds of formula I: in free or salt or solvate form, where R1, R2, R3 and R20 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. These compounds are useful for the treatment of inflammatory or obstructive airways diseases such as pulmonary hypertension, pulmonary fibrosis, liver fibrosis, cancer, muscle diseases such as muscle atrophies and muscle dystrophies, and systemic skeletal disorders such as osteoporosis.
    Type: Application
    Filed: October 15, 2008
    Publication date: August 19, 2010
    Inventors: Duncan Shaw, Catherine Leblanc, Dimitrios Lizos, Cathy Ritchie, Vikki Furminger, Sarah Lewis, Benoit Hornsperger, Nikolaus Johannes Stiefl, Sven Weiler
  • Organic compounds
    Publication number: 20100204225
    Abstract: There are provided according to the invention compounds of formula (I), in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.
    Type: Application
    Filed: February 3, 2010
    Publication date: August 12, 2010
    Inventors: Kamlesh Jagdis Bala, Catherine Leblanc, David Andrew Sandham, Katharine Louise Turner, Simon James Watson, Lyndon Nigel Brown, Brian Cox
  • 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS
    Publication number: 20100093690
    Abstract: Compounds of formula I in free or salt form, wherein R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: December 17, 2009
    Publication date: April 15, 2010
    Inventors: Ian Bruce, Peter Finan, Catherine LeBlanc, Clive McCarthy, Lewis Whitehead, Nicola Press, Graham Charles Bloomfield, Judy Hayler, Louise Kirman, Mrinalini Sachin Oza, Lena Shukla
  • PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY
    Publication number: 20100087432
    Abstract: There are provided according to the invention compounds of formula (I) as CRTh2 antagonists. In free or salt form, wherein R3, R4, R5, R6, Q, W and n are as described in the specification, process for preparing them, and their use as pharmaceuticals.
    Type: Application
    Filed: December 12, 2005
    Publication date: April 8, 2010
    Inventors: Claire Adcock, Catherine Leblanc, David A. Sandham, Simon J. Watson
  • 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors
    Patent number: 7687637
    Abstract: Compounds of formula I in free or salt form, wherein R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: March 30, 2010
    Assignee: Novartis AG
    Inventors: Ian Bruce, Peter Finan, Catherine Leblanc, Clive McCarthy, Lewis Whitehead, Nicola Press, Graham Charles Bloomfield, Judy Hayler, Louise Kirman, Mrinalini Sachin Oza, Lena Shukla
  • Organic compounds for the treatment of inflammatory or allergic conditions
    Patent number: 7678826
    Abstract: Compounds of formula (I) in free or pharmaceutically acceptable salt form, where R1, R2, R3, R4, R5, R6, R7, m, n, w, X, and Y have the meanings as indicated in the specification, are useful for treating conditions mediated by the CRTh2 receptor, especially inflammatory or obstructive airways diseases.
    Type: Grant
    Filed: May 22, 2006
    Date of Patent: March 16, 2010
    Inventors: Jake Axford, Urs Baettig, Brian Cox, Kamlesh Jagdis Bala, Catherine LeBlanc, David Andrew Sandham
  • Pyrrolopyridine derivatives and their use as Crth2 antagonists
    Patent number: 7666878
    Abstract: There are provided according to the invention compounds of formula (I), in free or salt form, wherein R1, R2, R3, R 4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.
    Type: Grant
    Filed: June 16, 2005
    Date of Patent: February 23, 2010
    Assignee: Novartis AG
    Inventors: Kamlesh Jagdis Bala, Catherine Leblanc, David Andrew Sandham, Katharine Louise Turner, Simon James Watson, Lyndon Nigel Brown, Brian Cox
  • Heterocyclic compounds as antiinflammatory agents
    Publication number: 20100041662
    Abstract: A compound of Formula Ia or Ib in free or salt or solvate form, where R1, R2, R3, R4, R5 R20, R24, R25, X, Y and Z have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. These compounds are also useful for treating diseases mediated by the Pi3k receptor, the JAK-2 receptor and the TRK receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: October 29, 2007
    Publication date: February 18, 2010
    Inventors: Sandrine Ferrand, Fraser Glickman, Catherine Leblanc, Cathy Ritchie, Duncan Shaw, Nikolaus Johannes Stiefl, Pascal Furet, Patricia Imbach, Frédéric Stauffer, Hans-Georg Capraro, François Gessier, Christoph Gaul, Pameia A. Albaugh, Greg Chopiuk
  • Organic compounds
    Publication number: 20090298824
    Abstract: Compounds of formula I in free or salt form, where Y, R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the CXCR2 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Application
    Filed: January 20, 2005
    Publication date: December 3, 2009
    Inventors: Neil J. Press, David Porter, Catherine Leblanc, Clive McCarthy, Nicolas Soldermann, Lyndon N. Brown
  • Organic compounds
    Publication number: 20090215776
    Abstract: Compounds of formula I in free or salt or solvate form, where T1, T2, X, Ra, Rb, R8 and R9 have the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle diseases and systemic skeletal disorders. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: January 2, 2009
    Publication date: August 27, 2009
    Inventors: Claire Adcock, Urs Baettig, Peter Hunt, Catherine Leblanc, Maude Nadine Pierrette Pipet, Robert Alexander Pulz, Katrin Spiegel, Nikolaus Johannes Stiefl
  • Organic Compounds
    Publication number: 20090209552
    Abstract: There are provided according to the invention compounds of formula (I) in free or salt form, wherein R3, R4, R5, R6a, R6b, Q and W are as described in the specification, process for preparing them, and their use as pharmaceuticals.
    Type: Application
    Filed: June 11, 2007
    Publication date: August 20, 2009
    Inventors: David Andrew Sandham, Catherine Leblanc, Claire Adcock, Kamlesh Jagdis Bala, Maude Nadine Pierrette Pipet
  • Pyrimidine derivatives as alk-5 Inhibitors
    Publication number: 20090209539
    Abstract: Compounds of formula (I) in free or salt or solvate form, where T1, T2, Ra and Rb have the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle diseases and systemic skeletal disorders. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: July 12, 2007
    Publication date: August 20, 2009
    Inventors: Catherine Leblanc, Maude Nadine Pierrette Pipet, Robin Alec Fairhurst, Claire Adcock, Robert Alexander Pulz, Duncan Shaw, Nikolaus Johannes Stiefl
  • Pyrrolopyrimidines and Pyrrolopyridines
    Publication number: 20090181941
    Abstract: Compounds of formula I in free or salt or solvate form, wherein X, T1, T3 and T4 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: January 9, 2009
    Publication date: July 16, 2009
    Inventors: Catherine Leblanc, Robert Alexander Pulz, Nikolaus Johannes Stiefl
  • Organic Compounds
    Publication number: 20080312322
    Abstract: A compound of formula (I); in free or pharmaceutically acceptable salt form, where R1, R2, R3, R4, R5, m, n, w, X, Y and Q have the meanings as indicated in the specification, are useful for treating conditions mediated by the CRTh2 receptor, especially inflammatory or obstructive airways diseases.
    Type: Application
    Filed: May 22, 2006
    Publication date: December 18, 2008
    Inventors: Urs Baettig, Brian Cox, Katharine Louise Turner, Simon James Watson, Diana Janus, Catherine Leblanc, David Andrew Sandham
  • Organic Compounds
    Publication number: 20080312229
    Abstract: There are provided according to the invention compounds of formula (I) in free or salt form, wherein R1, R2, R4, R5, R6, A, D, X, W, m and n are as described in the specification, process for preparing them, and their use as pharmaceuticals.
    Type: Application
    Filed: December 7, 2006
    Publication date: December 18, 2008
    Inventors: David Andrew Sandham, Catherine Leblanc, Harinder Pal Singh, Lyndon Nigel Brown
  • Organic Compounds
    Publication number: 20080287416
    Abstract: There are provided according to the invention compounds of formula (I) in free ors salt form, wherein R1, R2, R4, R5, R6, A, D, X, W, m and n are as described in the specification, process for preparing them, and their use as pharmaceuticals.
    Type: Application
    Filed: December 7, 2006
    Publication date: November 20, 2008
    Inventors: David Andrew Sandham, Catherine Leblanc, Lyndon Nigel Brown
  • 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases
    Publication number: 20080280871
    Abstract: in free or salt form, wherein Ra, Rb, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Application
    Filed: August 27, 2004
    Publication date: November 13, 2008
    Applicant: NOVARTIS AG
    Inventors: Graham Charles Bloomfield, Ian Bruce, Judy Fox Hayler, Catherine Leblanc, Darren Mark Le Grand, Clive McCarthy
  • Crth2 Receptor Antagonists
    Publication number: 20080269335
    Abstract: There are provided according to the invention compounds of formula (I) in free or salt form, wherein R<1>, R<2>, R<3>, X, Y, Z, m, and n are as described in the specification, process for preparing them, and their use as pharmaceuticals.
    Type: Application
    Filed: May 3, 2005
    Publication date: October 30, 2008
    Inventors: David Andrew Sandham, Katharine Louise Turner, Catherine Leblanc